DYN Q4 2024 Earnings — Dyne Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

DYNDyne Therapeutics, Inc.

$3B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$97M

Net Income

-$90M

EPS (Diluted)

$-0.88

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$84M

Free Cash Flow

-$85M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$691M

Total Liabilities

$61M

Stockholders' Equity

$630M

Cash & Equivalents

$435M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$97M	-$68M	-43.5%
Net Income	-$90M	-$67M	-34.4%